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he Calm After the Storm
ong-Term Survival
fter Cardiogenic Shock*
udith S. Hochman, MD, FACC,
enato Apolito, MD
ew York, New York
ardiogenic shock (CS) after acute myocardial infarction
MI) is a complex syndrome that involves a cascade of acute
eft ventricular dysfunction, decreased cardiac output, hypo-
ension, and tissue hypoperfusion. In the past decade our
nderstanding of this syndrome has been expanded, and
mportant strides have been made in improving the survival
f CS patients. Early mechanical revascularization, using
ither percutaneous coronary intervention or coronary artery
ypass graft (CABG) surgery, along with supportive care,
mproves short-term survival in these patients when com-
ared with initial medical stabilization using thrombolytic
gents, intra-aortic balloon pump insertion, and intensive
upportive care with or without delayed revascularization
1). However, CS remains a leading cause of death in
atients hospitalized with MI. Even with early revascular-
zation, the short-term mortality rate is high, and fewer than
0% survive to 1 year (1,2). But what becomes of those who
urvive beyond 1 year?
See page 1752
In this issue of the Journal, Singh et al. (3) address this
uestion and add to our understanding of the long-term
utcome of patients with CS complicating MI who survive
eyond 30 days by evaluating the large cohort of patients
nrolled at U.S. sites in the GUSTO (Global Use of
trategies to Open Occluded Coronary Arteries)-I trial (3).
heir analysis of patients treated with fibrinolytic therapy
or ST-segment elevation MI compared the long-term
urvival of the 1,891 (8.3%) patients who developed CS
ith the 20,992 (91.7%) patients who did not by using the
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merican College of Cardiology.
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The investigators found the 30-day survival of patients
ith CS to be expectedly poor at 50.4%, compared with
8.9% in those without CS. However, the remarkable
nding of this study is that the mortality rate of patients
ith CS, although also high at 1 year, stabilized and
pproximated that of patients without CS between years 2
nd 11, yielding annualized mortality rates of 2% to 4% per
ear for each group.
The observation that long-term outcome is relatively
ood for shock survivors is supported by smaller observa-
ional studies and the long-term follow-up of the SHOCK
Should We Emergently Revascularize Occluded Coronar-
es for Cardiogenic Shock) trial (2,4–7). Although the
ortality rate for patients in the initial medical stabilization
roup who survived to hospital discharge in the SHOCK
rial was high in the first year, it was lower in the emergency
evascularization group, and for both groups it stabilized
ver the 11-year follow-up (5). The older age at entry, lack
f selection for fibrinolytic-eligible patients presenting
ithin 6 h of MI, and other comorbidities likely explain the
igher (8% per year) late mortality rate for the early
evascularization group in the SHOCK trial compared with
he GUSTO trial shock survivors. Collectively these studies
how that, although in-hospital survival was poor and the
arge majority of CS patients will not be alive at late
ollow-up, those who survived to discharge had a relatively
ow mortality rate at late follow-up.
The data in the GUSTO trial and other studies are
nsufficient to evaluate the potential further reduction in
hese mortality rates with current optimal therapy, including
mplantable defibrillators. In the GUSTO trial, indepen-
ent predictors of higher mortality through 11 years for all
0-day survivors included age, shock, higher Killip class,
erebrovascular disease, prior MI, prior CABG, hyperten-
ion, diabetes, and anterior location of MI. Advancing age
merged as the most powerful predictor of both 30-day and
1-year mortality in both CS and non-CS cohorts. Remark-
bly, elderly 30-day survivors had similar 11-year outcomes
hether or not they had shock. Age was not associated with
orse functional status at 1 year after shock (8). These data
nd the long-term follow up of the SHOCK trial showing a
imilar treatment effect for early revascularization independent
f age support the American College of Cardiology/American
eart Association 2004 Guidelines for the Management of
T-Segment Elevation Myocardial Infarction Class IIA
ecommendation for the elderly: “patients with good prior
unctional status who are eligible for revascularization and
gree to invasive care may be selected for such an invasive
trategy” (9).
It is noteworthy that the current study found overall
ortality to be significantly lower in those receiving throm-
olytic therapy 2 h from presentation, confirming the
ritical importance of very early reperfusion. This is the only
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Editorial Comment October 30, 2007:1759–60herapy known to prevent CS. Although the finding that
ercutaneous coronary intervention during the index hospi-
alization was associated with a significant improvement in
urvival in CS was expected (because of a treatment benefit
s well as selection bias), a mortality benefit was not noted
or patients treated with CABG surgery during the index
ospitalization. This finding is in contrast to that of the
andomized SHOCK trial and numerous registries and was
bserved despite the bias that reflects selection of less ill
atients with shock for CABG, often after shock has
esolved (1). The reason for this GUSTO finding is unclear
ut may be attributable to the small cohort or unidentified
onfounders. It is possible that the rate of perioperative
eaths differs based on the volume of patients with CS who
ndergo surgery at a particular center and would suggest
hat regionalization of care may be appropriate for these
ighly complex and unstable patients.
A few other findings reported by Singh et al. (3) deserve
ention. The average systolic blood pressure in the CS
ohort at study entry was 116 mm Hg, and most (87.8%)
ere either Killip class I or II at baseline. Cardiogenic shock
eveloped in the vast majority of patients after hospital
resentation and presumably after initial therapy, raising the
uestion, “How often is there an iatrogenic contribution to
S?” The CS cohort had an unusually high rate (43%) of
evere bleeding. Patients with large infarcts will not tolerate
leeding, and a mixed shock picture may have been present
n some.
The finding that long-term outcome for 1-year survivors
f CS is similar to that of nonshock acute MI survivors
oints to the importance of improving short-term survival,
hich remains unacceptably low. This should place the
ocus on very early reperfusion in MI to prevent shock and
ovel therapies targeting patients with CS. Efforts to
mprove early survival are only made more important by the
bservation that survivors will likely enjoy good quality of
ife; most will be in New York Heart Association functional
lass I or II at 1 year of follow-up (1,4,8). Further improving
hort-term outcomes has proven challenging. Recent at-
empts to inhibit inflammatory cytokine and nitric oxide-
ediated systemic inflammatory response syndrome path-
ays in CS have yielded disappointing results (10,11).
imilarly, clinical outcomes were not improved in small
rials of percutaneous left ventricular assist devices.
The similar long-term outcomes for survivors of MI with
nd without shock reported by Singh et al. (3) suggest that
he cup can be viewed as half full—approximately one-half
f patients with shock complicating MI will be alive at 1ear, with a long-term prognosis determined largely by
ypical CV risk factors. Most will lead active lives with good
uality. We must rise to the challenge of preventing shock
ith very early reperfusion, avoiding iatrogenic shock,
ncreasing use of early revascularization despite its potential
mpact on physician “scorecards,” and developing novel
herapies to treat shock.
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venue, Skirball 9R, New York, New York 10016. E-mail:
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